Test Your Expertise in the Early Diagnosis of Genetically Based Metabolic Disease: A Medical Simulation is organized by Medscape, LLC.
CME Released: July 16, 2024
Valid for credit through: July 16, 2025
Description:
The goal of this activity is for learners to be better able to enhance their ability to make an early diagnosis of molybdenum cofactor deficiency (MoCD) type A. Performance-level outcomes related to the diagnosis of MoCD type A will be assessed.
Learning Objectives:
Upon completion of this activity, participants will:
• Demonstrate improved performance associated with
• Ordering tests to evaluate metabolic disease
• Diagnosing patients presenting with neurological abnormalities
Accreditation Statements
In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
For Physicians
• Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
• The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
• College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.
Copyrights © 2026 eMedEvents Corporation, All Rights Reserved